HIGHLIGHTS FROM ELCC 2024
Your direct line with Prague
With the educational support of:
DOWNLOAD AVAILABLE
Highlights from the 2024 European Lung Cancer Conference (ELCC)
Daily highlights
Dr Karolien Vekens, pulmonologist at the University Hospital Brussels discusses three amivantamab-related abstracts presented during the second mini oral session at ELCC 2024.
Amivantamab is an EGFR and MET directed
Dr Anouk Goudsmit, medical oncologist at the Institut Jules Bordet in Brussels, discusses the highlights of the third mini oral session at ELCC 2024.
During this session, two main topics
Prof Mariana Brandão, medical oncologist at Institute Jules Bordet, Hôpital Universitaire de Bruxelles shares her insights from the proffered paper session. Updated results from the FLAURA-2 trial were presented, including
Dr Jo Raskin, thoracic oncologist at Antwerp University Hospital summarises the first mini oral session.
In ES-SCLC, the standard treatment involves platinum and etoposide with immunotherapy, based on the phase
In depth
Previously presented results of the phase III FLAURA-2 trial have demonstrated a benefit in progression-free survival (PFS) with a first line combination of osimertinib and platinum-based chemotherapy compared to osimertinib
Previously presented results of the phase III FLAURA-2 trial have demonstrated a benefit in progression-free survival (PFS) with a first line combination of osimertinib and platinum-based chemotherapy compared to osimertinib
The contemporary management of patients with stage III NSCLC has been one of the main talking points at the 2024 European Lung Cancer Conference. During several animated debates specialists shared
One of the main talking points during the 2024 European Lung Cancer Conference was the integration of immunotherapy in the peri-operative treatment of patients with early-stage non-small cell lung cancer
The optimal management of stage III NSCLC continues to be a subject of intense discussion. During the 2024 European Lung Cancer Conference (ELCC), a debate was organized in which Prof
The 2024 edition of ELCC featured the presentation of the new TNM classification for lung cancer. To discuss this 9th edition of the TNM classification, Prof Dr Mariana Brandão, medical
During ELCC 2024, Dr Kristof Cuppens, pulmonologist and thoracic oncologist at the Jessa Hospital in Hasselt, chaired a session discussing the remaining challenges surrounding the integration of immunotherapy in the
Posters
Dr Jordi Remon Masip, medical oncologist at Institut Gustave Roussy, Villejuif, France presents PULSE, a non-inferiority study of maintenance pembrolizumab at usual or low dose (based on increased interval time
Dr László Urbán, pulmonologist from the Matrahaza University and Teaching Hospital, Matrahaza, Hungary presents updated safety data with ∼9 months additional study follow-up of the AEGEAN trial with perioperative durvalumab
Prof Frank Griesinger, medical oncologist at Pius Hospital, Oldenburg, Germany presents real-world data and outcomes in the US and Germany after first-line treatment with osimertinib in patients with EGFRm
Dr Vincent Geldhof from AZ Klina in Brasschaat presented a multicenter study on real-world treatment practices for lung cancer patients receiving immune checkpoint inhibitors. The study analyzed 597 variables, mapping
Yuelin Han, student at the Tongji Hospital, Wuhan, China presents a systematic review and network meta-analysis evaluating the the efficacy and safety of perioperative immunotherapy combinations for resectable NSCLC.
Dr Olivier Van Kerkhove, pulmonologist in training at UZ Leuven presented a propensity-based analysis of SBRT and VATS for early-stage lung cancer that can guide data-driven support and decision-making in
Prof Mariana Brandão, medical oncologist at Institute Jules Bordet, Hôpital Universitaire de Bruxelles presents a phase I/IIa study that aims to investigate the efficacy and safety of dry powder inhaled